Effect of Latanoprostene Bunod Ophthalmic Solution 0.024% on Episcleral Venous Pressure and Outflow Facility in Ocular Hypertensive Subjects

  • STATUS
    Recruiting
  • days left to enroll
    88
  • participants needed
    34
  • sponsor
    Bausch & Lomb Incorporated
Send
Updated on 29 October 2022
See if I qualify
screening examination
corrected visual acuity
ophthalmic solution
brimonidine tartrate ophthalmic solution
intraocular pressure
aqueous humor
ocular hypotensive
hypotensive
optic neuropathy

Summary

The primary objective of this study is to determine the effect of latanoprostene bunod (LBN) ophthalmic solution 0.024% (a single dose and 7 days of once daily [QD] dosing) on 2 aspects of aqueous humor (AqH) dynamics (episcleral venous pressure [EVP] and outflow facility) in participants with ocular hypertension (OHT).

Description

All participants will receive both the investigational (LBN ophthalmic solution 0.024%) and placebo treatments, with 1 eye receiving LBN 0.024% and the contralateral eye receiving placebo. Each participant will be randomized as to which eye (right or left) will receive LBN 0.024% versus placebo.

All participants will undergo a minimum 14-day to maximum 42-day washout period prior to the start of study drug administration.

Details
Condition Ocular Hypertension
Treatment Placebo, Latanoprostene Bunod, Latanoprostene Bunod
Clinical Study IdentifierNCT04140279
SponsorBausch & Lomb Incorporated
Last Modified on29 October 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

General Inclusion Criteria
Participants must be able to read, understand, and provide written informed consent on the Institutional Review Board (IRB) approved informed consent form (ICF) and are able and willing to comply with all treatment and follow-up/study procedures
Females of childbearing potential must have a negative urine pregnancy test result at the screening examination and must agree to use an acceptable method of contraception throughout their participation in the study
Ocular Inclusion Criteria
Participants must have a diagnosis of OHT in both eyes (intraocular pressure [IOP] ≥22 mmHg prior to starting treatment with IOP-lowering medication) without evidence of glaucomatous optic neuropathy or visual field loss and must also have been receiving IOP-lowering medication for ≥3 months prior to Screening (Visit 1)
Participants must undergo a washout of any existing ocular hypotensive medications in order to determine eligibility. Washout period will vary with the class of medication used (2-6 weeks)
Participants must meet the following IOP requirements at Visit 3 (Eligibility Visit at End of Washout)
Intraocular pressure ≥22 mmHg and ≤32 mmHg in both eyes
An increase in IOP of 20% over the Screening (Visit 1) IOP
The difference in IOP between eyes ≤4 mmHg
Participants must have a best corrected visual acuity (BCV A) in each eye of 20/50
(logarithm of the minimum angle of resolution [logMAR] +0.4) or better

Exclusion Criteria

General Exclusion Criteria
Participation in any drug or device clinical investigation within 30 days prior to Visit 1 (Screening) or anticipation of participating in any other drug or device clinical investigation within the duration of this study
Participants with a history or presence of chronic generalized systemic disease that the Investigator feels might increase the risk to the participant or confound the results of the study
Female participants who are pregnant or breastfeeding
Drug Therapies
Participants with known hypersensitivity or contraindications to latanoprostene bunod or any of the ingredients in the study drugs
Participants with an anticipated need to initiate or modify medication (systemic or topical) that is known to affect IOP (for example, steroids, α-adrenergic agonists, β-adrenergic antagonists, calcium channel blockers, angiotensin-converting enzyme [ACE] inhibitors, and angiotensin II receptor blockers)
Ocular Exclusion Criteria
Diseases
Participants who are unable to discontinue contact lens use during and for 15 minutes following instillation of study drug and for 24 hours before check-in and during each study visit
Participants with a central corneal thickness less than 480 μm or greater than 600 micrometer (μm) in either eye
Participants with any condition that prevents reliable applanation tonometry (for example, significant corneal surface abnormalities) in either eye
Participants who are monocular
Participants with ocular conditions, which, in the opinion of the Investigator, will impact the study measurements, such as
Active optic disc hemorrhage in either eye
Current or a history of central/branch retinal vein or artery occlusion in either eye
Current or a history of macular edema in either eye
Very narrow angles (3 quadrants with less than Grade 2 according to Shaffer's anterior chamber angle grading system) and participants with angle closure, congenital, and secondary glaucoma, and with history of angle closure in either eye
Diagnosis of a clinically significant or progressive retinal disease (for example, diabetic retinopathy, exudative or severe non-exudative macular degeneration) in either eye
Myopia greater than -4.00 diopter (D), or hyperopia greater than +2.000
Participants with any intraocular infection or inflammation in either eye within 3
Surgery
months prior to Visit 1 (Screening)
Participants with a history of ocular laser surgery in either eye within the 3 months (90 days) prior to Visit 1 (Screening)
Participants with a history of laser trabeculoplasty, cyclophotocoagulation or glaucoma surgical procedures at any time prior to Visit 1 (Screening)
Participants with a history of incisional ocular surgery other than routine uncomplicated cataract surgery or severe trauma in either eye within the 3 months (90 days) prior to Visit 1 (Screening)
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

screening examination
corrected visual acuity
ophthalmic solution
brimonidine tartrate ophthalmic solution
intraocular pressure
aqueous humor
ocular hypotensive
hypotensive
optic neuropathy

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note